Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, working as a dual GLP-1/GIP receptor agonist that targets both the GLP-1 and GIP receptors instead of GLP-1 alone, which enhances fat metabolism and insulin sensitivity beyond a single-receptor peptide
Compounded semaglutide is not FDA-approved, is not the same as these brand-name products, and has not been reviewed by the FDA for safety or effectiveness
Beyond their role in weight management, GLP-1R agonists have shown neuroprotective and neurotrophic properties, offering potential benefits in reducing neuroinflammation
Individual results varied widely - some participants lost significantly more, some lost less, and some did not lose substantial weight even on the highest doses
Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
Weight Management and Body Composition : Sustainable weight loss with possible preservation of lean muscle helps maintain healthier body composition over time
.png)
